Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges
The DOI matches its Crossref record; 176 of the 177 references it cites were found in a registry or an index.
Abstract
In vivo gene replacement for the treatment of inherited disease is one of the most compelling concepts in modern medicine. Adeno-associated virus (AAV) vectors have been extensively used for this purpose and have shown therapeutic efficacy in a range of animal models. Successful translation to the clinic was initially slow, but long-term expression of donated genes at therapeutic levels has now been achieved in patients with inherited retinal disorders and haemophilia B. Recent exciting results have raised hopes for the treatment of many other diseases. As we discuss here, the prospects and challenges for AAV gene therapy are to a large extent dependent on the target tissue and the specific disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This immune cascade model might explain why re-administration in patients could become difficult, and why the administration of rAAVs in patients with high neutralizing antibodies (nAbs) are generally not included in clinical trials [327].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [327]
Citations
Cites
The Danger Model: A Renewed Sense of Self
Matzinger, P. (2002) · Science · doi:10.1126/science.1071059 · Cited by 4,205
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Genome editing with engineered zinc finger nucleases
Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S., & Gregory, P. D. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2842 · Cited by 2,285
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationSafety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Self-citationProphylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067659 · Cited by 1,950 · cited 1×
“The disease is currently treated by intravenous infusion of clotting factor concentrate”
BackgroundEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Research works printed but not linked: 3
- Basner-Tschakarjan, E. et al. Dose-dependent activation of capsid-specific T cells after AAV serotype 8 vector administration in a clinical study for hemophilia. Mol. Ther. (in the press).
- Mingozzi, F. et al. Modulation of T cell response to the AAV capsid in subjects undergoing intramuscular gene transfer for lipoprotein lipase deficiency. Hum. Gene Ther. 19, 1090 (2008).
- Muzyczka, N. & Berns, K. I. in Parvoviridae: The Viruses and their Replication (eds Knipe, D. M. & Howley, P. M.) 2437–2477 (Lippincott, Williams and Wilkins, Philadelphia, 2001).
Cited by
Items 301–400 of 892
Intelligent Hydrogel-Assisted Hepatocellular Carcinoma Therapy
Tang, Z., Deng, L., Zhang, J., Jiang, T., Xiang, H., Chen, Y., Liu, H., Cai, Z., Cui, W., & Xiong, Y. (2024) · Research · doi:10.34133/research.0477 · Cited by 60
Zhen, S., & Li, X. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000486168 · Cited by 51
Adipose tissue insulin receptor knockdown via a new primate-derived hybrid recombinant AAV serotype
Liu, X., Magee, D., Wang, C., McMurphy, T. B., Slater, A., During, M. J., & Cao, L. (2014) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2013.8 · Cited by 51
Rogers, G. L., Martino, A. T., Zolotukhin, I., Ertl, H. C., & Herzog, R. W. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-25 · Cited by 45
Noncationic Material Design for Nucleic Acid Delivery
Jiang, Z., & Thayumanavan, S. (2020) · Advanced Therapeutics · doi:10.1002/adtp.201900206 · Cited by 49
Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.099 · Cited by 45
“Recombinant AAV (rAAV) vectors are currently in use in a number of gene therapy clinical trials and have shown remarkable efficacy in the treatment of Leber’s congenital amaurosis, hemophilia B, and aromatic L-amino acid carboxylase deficiency (Mingozzi and High, 2011).”
Wang, Z., Lisowski, L., Finegold, M. J., Nakai, H., Kay, M. A., & Grompe, M. (2012) · Molecular Therapy · doi:10.1038/mt.2012.157 · Cited by 44
Knabel, M. K., Ramachandran, K., Karhadkar, S. S., Hwang, H., Creamer, T. J., Chivukula, R. R., Sheikh, F. H., Clark, K. R., Torbenson, M. S., Montgomery, R. A., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124411 · Cited by 47
Nanoscale bio-platforms for living cell interrogation: current status and future perspectives
Chang, L., Hu, J., Chen, F., Chen, Z., Shi, J., Yang, Z., Li, Y., & Lee, L. J. (2015) · Nanoscale · doi:10.1039/c5nr06694h · Cited by 45
CRISPR/Cas9-mediated correction of human genetic disease
Men, K., Duan, X., He, Z., Yang, Y., Yao, S., & Wei, Y. (2017) · Science China Life Sciences · doi:10.1007/s11427-017-9032-4 · Cited by 50
A New Tool for CRISPR-Cas13a-Based Cancer Gene Therapy
Gao, J., Luo, T., Lin, N., Zhang, S., & Wang, J. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.09.004 · Cited by 51
Sondhi, D., Scott, E., Chen, A., Hackett, N. R., Wong, A. M. S., Kubiak, A., Nelvagal, H. R., Pearse, Y., Cotman, S. L., Cooper, J. D., et al. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.253 · Cited by 44
“…storage disorders and leukodystrophies, and has also been used in clinical trials ( Janson et al., 2002; Crystal et al., 2004; Sands and Davidson, 2006; Worgall et al., 2008; Bowers et al., 2011; Gritti, 2011; Mingozzi and High, 2011; Leone et al., 2012; Rafi et al., 2012; Tomanin et al., 2012).”
MethodA strategy for Cas13 miniaturization based on the structure and AlphaFold
Zhao, F., Zhang, T., Sun, X., Zhang, X., Chen, L., Wang, H., Li, J., Peng, F., Lai, L., Sui, T., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41320-8 · Cited by 47
“The interaction sites were concentrated in α -helix9,10,12,13 of RfxCas13d (Fig.”
Ge, H., Baribault, H., Vonderfecht, S., Lemon, B., Weiszmann, J., Gardner, J., Lee, K. J., Gupte, J., Mookherjee, P., Wang, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033603 · Cited by 44
“the AAV gene delivery method ([28], JS unpublished observations).”
MethodTian, K., Chen, P., Liu, Z., Si, S., Zhang, Q., Mou, Y., Han, L., Wang, Q., & Zhou, X. M. (2017) · Oncotarget · doi:10.18632/oncotarget.17723 · Cited by 51
“Importantly, they are capable of promoting persistent gene expression in multiple somatic tissues of animals compared with adenovirus and currently being tested in several clinical trials [26].”
BackgroundCRISPR/Cas9: at the cutting edge of hepatology
Pankowicz, F. P., Jarrett, K. E., Lagor, W. R., & Bissig, K. (2017) · Gut · doi:10.1136/gutjnl-2016-313565 · Cited by 47
“AAV vectors have been used successfully in over 120 clinical trials to date 133 134 (http://www.clinicaltrials.gov), with only little vector-related toxicity or adverse events.”
MethodExosomes: Structure, Biogenesis, Types and Application in Diagnosis and Gene and Drug Delivery
Agarwal, S., Agarwal, V., Agarwal, M., & Singh, M. (2020) · Current Gene Therapy · doi:10.2174/1566523220999200731011702 · Cited by 48
Adeno-Associated Virus Serotype 2–hCHM Subretinal Delivery to the Macula in Choroideremia
Alemán, T. S., Huckfeldt, R. M., Serrano, L. W., Pearson, D. J., Vergilio, G. K., McCague, S., Marshall, K. A., Ashtari, M., Doan, T. M., Weigel-DiFranco, C., et al. (2022) · Ophthalmology · doi:10.1016/j.ophtha.2022.06.006 · Cited by 42
Petrosyan, H. A., Alessi, V., Singh, V., Hunanyan, A. S., Levine, J. M., & Arvanian, V. L. (2014) · Gene Therapy · doi:10.1038/gt.2014.74 · Cited by 44
Mallol, C., Casana, E., Jiménez, V., Casellas, A., Haurigot, V., Jambrina, C., Sacristan, V., Morró, M., Agudo, J., Vilà, L., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.05.007 · Cited by 46
“In vivo gene transfer of therapeutic candidate genes through adenoassociated viral (AAV) vectors may offer the possibility of lifelong beneficial effects after a one-time treatment, as the production of therapeutic proteins for extended periods of time after a single administration of these vectors has repeatedly been…”
BackgroundEnhancement of the liver’s neuroprotective role ameliorates traumatic brain injury pathology
Dai, Y., Dong, J.-H., Wu, Y. H., Zhu, M., Xiong, W., Li, H., Zhao, Y., Hammock, B. D., & Zhu, X. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2301360120 · Cited by 47
“Owing to its unique anatomical properties, the liver is the preferred target for AAV-based gene therapy (45).”
Differential myofiber-type transduction preference of adeno-associated virus serotypes 6 and 9
Riaz, M., Raz, Y., Moloney, E. B., van Putten, M., Krom, Y. D., van der Maarel, S. M., Verhaagen, J., & Raz, V. (2015) · Skeletal Muscle · doi:10.1186/s13395-015-0064-4 · Cited by 42
“In the last couple of decades, several AAV serotypes have been developed for effective gene delivery into various tissues including skeletal muscle with AAV vectors emerging as promising vehicles in clinical trials for monogenic musculoskeletal diseases including Duchenne and limbgirdle muscular dystrophy [23, 24].”
MiR-384 inhibits human colorectal cancer metastasis by targeting KRAS and CDC42
Wang, Y., Chen, Y., Liu, S., Ye, Y., Jiao, H., Wang, S., Xiao, Z., Wei, W., Qiu, J., Li, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12704 · Cited by 41
“MiRNAs, with the tendency of accumulating in hepatic tissue, promise more efficacy in suppressing liver metastatic colonization [21].”
BackgroundGene therapy for achromatopsia
Michalakis, S., Schön, C., Becirovic, E., & Biel, M. (2017) · The Journal of Gene Medicine · doi:10.1002/jgm.2944 · Cited by 41
Huang, W., Liu, X., Queen, N. J., & Cao, L. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.06.002 · Cited by 41
“In this regard, viral vectors have become an attractive alternative delivery vehicle, in particular, recombinant adeno-associated virus (rAAV) vectors, because they can transduce both dividing and postmitotic tissues, with low immunogenicity and long-lasting transgene expression without stimulating a cell-mediated imm…”
RNA-guided piggyBac transposition in human cells
Hew, B. E., Sato, R., Mauro, D., Stoytchev, I., & Owens, J. B. (2019) · Synthetic Biology · doi:10.1093/synbio/ysz018 · Cited by 46
Naiki, Y., Miyado, M., Horikawa, R., Katsumata, N., Onodera, M., Pang, S., Ogata, T., & Fukami, M. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej16-0112 · Cited by 40
Anti-hIgE gene therapy of peanut-induced anaphylaxis in a humanized murine model of peanut allergy
Pagovich, O. E., Wang, B., Chiuchiolo, M. J., Kaminsky, S. M., Sondhi, D., Jose, C. L., Price, C. C., Brooks, S. F., Mezey, J. G., & Crystal, R. G. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.03.053 · Cited by 43
Targeted Gene Delivery: Where to Land
Pavani, G., & Amendola, M. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.609650 · Cited by 55
“Conventional gene therapy approach consists of the addition of a functional copy of a mutated gene to patients’ cells using viral vectors, such as adeno-associated virus (AAV) (Mingozzi and High, 2011) and lentivirus (LV)-derived vectors (Naldini, 2011).”
BackgroundWu, Q. J., Gong, C. Y., Luo, S. T., Zhang, D. M., Zhang, S., Shi, H., Lu, L., Yan, H., He, S., Li, D. D., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-129 · Cited by 43
The structure of AAVrh32.33, a novel gene delivery vector
Mikals, K., Nam, H.-J., Van Vliet, K., Vandenberghe, L. H., Mays, L. E., McKenna, R., Wilson, J. M., & Agbandje-McKenna, M. (2014) · Journal of Structural Biology · doi:10.1016/j.jsb.2014.03.020 · Cited by 41
“Several AAV serotypes, including AAV1, AAV2, and AAV8, have been used in human clinical trials (Maguire et al., 2009; Mingozzi and High, 2011a; Nathwani et al., 2011).”
Prevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B
Nayak, S., Sarkar, D., Perrin, G. Q., Moghimi, B., Hoffman, B. E., Zhou, S., Byrne, B. J., & Herzog, R. W. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00244 · Cited by 40
“Memory CD8+ T cell responses to capsid are also known to occur and may target transduced cells (Manno et al., 2006; Mingozzi et al., 2007b; Li et al., 2011; Mingozzi and High, 2011a).”
BackgroundInfluentialStructure-guided AAV capsid evolution strategies for enhanced CNS gene delivery
Gonzalez, T. J., Mitchell-Dick, A., Blondel, L. O., Fanous, M. M., Hull, J. A., Oh, D. K., Møller-Tank, S., Rivera, R. M. C., Piedrahita, J. A., & Asokan, A. (2023) · Nature Protocols · doi:10.1038/s41596-023-00875-y · Cited by 42
Gene therapy in cystic fibrosis
Prickett, M. H., & Jain, M. (2012) · Translational research · doi:10.1016/j.trsl.2012.12.001 · Cited by 46
Adeno-Associated Virus-Mediated MicroRNA Delivery and Therapeutics
Xie, J., Burt, D. R., & Gao, G. (2015) · Seminars in Liver Disease · doi:10.1055/s-0034-1397352 · Cited by 45
Cai, J., Yue, Y., Wang, Y., Jin, Z., Jin, F., & Wu, C. C. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.07.031 · Cited by 45
Adeno-Associated Virus Vectors and Stem Cells: Friends or Foes?
Brown, N. J., Song, L., Rao, K. N., & Hirsch, M. L. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.038 · Cited by 43
“Previous studies have shown that AAV vectors can be found in the urine, semen, and blood serum of human patients several months post injection with vectors, showing that AAV vectors can be shed from patients into the environment.(173,174) Furthermore, evidence for potential AAV vector production within the patient and…”
BackgroundWu, Y., Jiang, L., Geng, H., Yang, T., Han, Z., He, X.-B., Lin, K., & Xu, F. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.05.005 · Cited by 41
Liu, K., Zhou, Z., Pan, M., & Zhang, L. (2021) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13618 · Cited by 40
Bertolin, J., Sánchez, V., Ribera, A., Jaén, M. L., García, M., Pujol, A., Sánchez, X., MUÑOZ, S. A., Marcó, S., Pérez, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25697-y · Cited by 44
An Emerging Adeno-Associated Viral Vector Pipeline for Cardiac Gene Therapy
Asokan, A., & Samulski, R. J. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.2515 · Cited by 38
“A summary of current knowledge pertaining to the biology, preclinical studies, and clinical applications of the different AAV serotypes and pertinent literature has been reviewed elsewhere (Agbandje-McKenna and Kleinschmidt, 2011; Mingozzi and High, 2011).”
BackgroundZeng, Y., Tseng, S. ‐., Kempson, I. M., Peng, S., Wu, W., & Liu, J. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.09.018 · Cited by 39
Harnessing the liver to induce antigen-specific immune tolerance
Gottwick, C., Carambia, A., & Herkel, J. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00942-8 · Cited by 43
Pandey, S., Jirásko, M., Lochman, J., Chvátal, A., Dvorakova, M. C., & Kučera, R. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091485 · Cited by 40
“The limitations of in vivo gene therapy are associated with gene silencing, mutations, non-specific gene expression, and immune reaction against the vector [85].”
BackgroundLing, C., Wang, Y., Feng, Y., Zhang, Y., Li, J., Hu, X.-R., Wang, L., Zhong, M., Zhai, X., Zolotukhin, I., et al. (2015) · Journal of Chinese Integrative Medicine · doi:10.1016/s2095-4964(15)60200-x · Cited by 38
Rescue of GSDIII Phenotype with Gene Transfer Requires Liver- and Muscle-Targeted GDE Expression
Vidal, P., Pagliarani, S., Colella, P., Verdera, H. C., Jauze, L., Gjorgjieva, M., Puzzo, F., Marmier, S., Collaud, F., Sola, M. S., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.12.019 · Cited by 42
“To this aim, adeno-associated virus (AAV) vectors represent the platform of choice for in vivo gene transfer.(8) Data obtained in the context of clinical trials for hemophilia,(9) congenital blindness,(10) and spinal muscular atrophy(11) demonstrate the safety and therapeutic potential of the AAV vector gene transfer…”
BackgroundSelf-citationKumar, B., Cashman, S. M., & Kumar‐Singh, R. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.03.012 · Cited by 38
Gene therapy and genome editing for primary immunodeficiency diseases
Zhang, Z., Thrasher, A. J., & Zhang, F. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.07.007 · Cited by 40
Optimization of AAV6 transduction enhances site-specific genome editing of primary human lymphocytes
Rogers, G. L., Huang, C., Clark, R. D. E., Seclén, E., Chen, H.-Y., & Cannon, P. M. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.09.003 · Cited by 42
“30 AAV is particularly versatile as a 63 gene therapy vector due to its relatively low immunogenicity, the variety of serotypes available 64 with tropism for different tissues, and the ability to persist as episomal, nonintegrated DNA for 65 upwards of a decade.(31) As such, most work using AAV has focused on in vivo…”
BackgroundZaiss, A. K., Foley, E. M., Lawrence, R., Schneider, L. S., Hoveida, H., Secrest, P., Catapang, A. B., Yamaguchi, Y., Alemany, R., Shayakhmetov, D. M., et al. (2015) · Journal of Virology · doi:10.1128/jvi.01939-15 · Cited by 41
“ise in clinical trials for treatment of a wide variety of diseases (1, 2).”
BackgroundGene therapy for hemophilia: past, present and future
George, L. A., & Fogarty, P. F. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.10.002 · Cited by 37
Neerincx, A., Jakobshagen, K., Utermöhlen, O., Büning, H., Steimle, V., & Kufer, T. A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401065 · Cited by 37
Wang, Y., Ling, C., Song, L., Wang, L., Aslanidi, G. V., Tan, M., Ling, C., & Srivastava, A. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.090 · Cited by 37
“…a codon-optimized human factor IX gene under the control of a liver-specific promoter have shown efficacy in preclinical models of hemophilia B gene therapy (Nathwani et al. , 2011) and have also yielded exciting results in a recent phase I clinical trial (Mingozzi and High, 2011; Ponder, 2011).”
InfluentialCardiovascular RNA Interference Therapy: The Broadening Tool and Target Spectrum
Poller, W. C., Tank, J., Skurk, C., & Gast, M. (2013) · Circulation Research · doi:10.1161/circresaha.113.301056 · Cited by 39
“first era the goal was the addition or substitution of proteincoding genes.(43,51,56,57) Below we discuss analogies and dif-”
BackgroundPerfluorocarbon-based nanomedicine: emerging strategy for diagnosis and treatment of diseases
Zhang, T., Zhang, Q., Tian, J., Xing, J., Guo, W., & Liang, X. (2018) · MRS Communications · doi:10.1557/mrc.2018.49 · Cited by 39
Zheng, R., Li, Y., Wang, L., Fang, X., Zhang, J., He, L., Yang, L., Li, D., & Geng, H. (2020) · Kidney International · doi:10.1016/j.kint.2020.04.049 · Cited by 37
The ice age – A review on formulation of Adeno-associated virus therapeutics
Grossen, P., Skaripa-Koukelli, I., van Haasteren, J., Machado, A. H. E., & Dürr, C. (2023) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2023.07.002 · Cited by 43
Zygmunt, D. A., Crowe, K. E., Flanigan, K. M., & Martin, P. T. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.141 · Cited by 36
“INTRODUCTION USE OF RECOMBINANT adeno-associated virus (rAAV) as a vector for delivery of gene therapies has become increasingly standard in clinical studies.(1) rAAV vectors have been used to deliver gene therapy to treat multiple diseases, including hemophilias, neurodegenerative diseases, neuropathies, cardiovascul…”
BackgroundRaigani, M., Eftekhari, Z., Adeli, A., & Kazemi‐Lomedasht, F. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102666 · Cited by 46
“65,66 This is typically achieved by removing or in-activating viral genes essential for replication and pathogenicity, while preserving or enhancing genes required for cell entry and gene transfer.”
Partial restoration of cardiac function with PDZ nNOS in aged mdx model of Duchenne cardiomyopathy
Lai, Y., Zhao, J., Yue, Y., Wasala, N. B., & Duan, D. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu029 · Cited by 38
MiR-298 Counteracts Mutant Androgen Receptor Toxicity in Spinal and Bulbar Muscular Atrophy
Pourshafie, N., Lee, P. R., Chen, K., Harmison, G. G., Bott, L. C., Katsuno, M., Sobue, G., Burnett, B. G., Fischbeck, K. H., & Rinaldi, C. (2016) · Molecular Therapy · doi:10.1038/mt.2016.13 · Cited by 35
Experimental therapies in the neuronal ceroid lipofuscinoses
Neverman, N. J., Best, H. L., Hofmann, S. L., & Hughes, S. M. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.04.026 · Cited by 35
β‐cell‐specific IL‐35 therapy suppresses ongoing autoimmune diabetes in NOD mice
Manzoor, F., Johnson, M. C., Li, C., Samulski, R. J., Wang, B., & Tisch, R. (2016) · European Journal of Immunology · doi:10.1002/eji.201646493 · Cited by 39
“AAV vectors, in conjugation with a number of capsid protein serotypes with varying cell tropism and tissue specific promoters, offer an approach to selectively transduce distinct tissues and obtain long-term cell-specific transgene expression in vivo [27, 31, 32].”
BackgroundJiang, Z., Cui, W., Prasad, P., Touve, M. A., Gianneschi, N. C., Mager, J., & Thayumanavan, S. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b01321 · Cited by 37
Lin, Y., Diao, Y., Du, Y., Zhang, J., Li, L., & Liu, P. (2021) · Microscopy Research and Technique · doi:10.1002/jemt.23893 · Cited by 37
“Therefore, it is regarded as one of the most promising gene therapy carriers (Flotte, 2004; Mingozzi & High, 2011).”
BackgroundEmmanuel, S. N., Smith, J. K., Hsi, J., Tseng, Y.-S., Kaplan, M., Mietzsch, M., Chipman, P. R., Asokan, A., McKenna, R., & Agbandje‐McKenna, M. (2021) · Journal of Virology · doi:10.1128/jvi.01251-21 · Cited by 36
Chen, M., Maeng, K., Nawab, A., Francois, R. A., Bray, J. K., Reinhard, M. K., Boye, S. L., Hauswirth, W. W., Kaye, F. J., Aslanidi, G., et al. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.089 · Cited by 42
“The remaining obstacles for pancreatic tropism includes, irrespective of the serotype employed, the persistence of vector dose-dependent immune response and the modest level of transduction efficacy.(27,28) A major barrier for AAV gene therapy is the degradation of viral particles during their intracellular traffickin…”
Tian, Y., Shi, H., Zhang, D., Wang, C., Zhao, F., Li, L., Xu, Z., Jiang, J., & Li, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.10.018 · Cited by 34
Zhang, W., Solanki, M., Müther, N., Ebel, M., Wang, J., Sun, C., Izsvák, Z., & Ehrhardt, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076771 · Cited by 38
“AAV vectors are broadly used in clinical applications and therefore this type of vector holds great promise for gene therapeutic applications [2,4].”
BackgroundPresent and Future of Adeno Associated Virus Based Gene Therapy Approaches
Ortolano, S., Spuch, C., & Navarro, C. (2012) · Recent Patents on Endocrine, Metabolic & Immune Drug Discovery · doi:10.2174/187221412799015245 · Cited by 35
Manipulation of spermatogonial stem cells in livestock species
Savvulidi, F. G., Ptáček, M., Vargová, K., & Stádník, L. (2019) · Journal of Animal Science and Biotechnology/Journal of animal science and biotechnology · doi:10.1186/s40104-019-0355-4 · Cited by 36
“material into the host genome is avoided [89].”
Proinsulin Slows Retinal Degeneration and Vision Loss in the P23H Rat Model of Retinitis Pigmentosa
Fernández‐Sánchez, L., Lax, P., Isiegas, C., Ayuso, E., Ruiz, J. M., de la Villa, P., Bosch, F., de la Rosa, E. J., & Cuenca, N. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.067 · Cited by 39
“Preclinical studies have shown that AAV vector–mediated gene transfer results in long-term gene expression in small and large animal models of disease (Mingozzi and High, 2011).”
Li, B., Ma, W., Ling, C., Vliet, K. V., Huang, L.-Y., Agbandje‐McKenna, M., Srivastava, A., & Aslanidi, G. (2015) · Human Gene Therapy Methods · doi:10.1089/hgtb.2015.115 · Cited by 35
“The use of recombinant AAV2 vectors has proven to be safe and, in a number of phase I/II clinical trials, has shown efficacy in gene therapy for at least five human diseases.(2) However, the use of large vector doses often needed to achieve therapeutic benefits is also associated with the risk of the host immune respo…”
BackgroundVilà, L., Elias, I., Roca, C., Ribera, A., Ferré, T., Casellas, A., Lage, R., Franckhauser, S., & Bosch, F. (2014) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2014.39 · Cited by 36
Split Cas9, Not Hairs − Advancing the Therapeutic Index of CRISPR Technology
Schmelas, C., & Grimm, D. (2018) · Biotechnology Journal · doi:10.1002/biot.201700432 · Cited by 35
Obstacles and future of gene therapy for hemophilia
Arruda, V. R., & Samelson-Jones, B. J. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1069179 · Cited by 33
“AAV has emerged as the principle vector for in vivo gene therapy [6].”
BackgroundRibas, V., & Costa, M. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00231 · Cited by 25
“Nevertheless, recombinant AAV vectors have one of the best characterized safety profile, and have emerged as an appropriate delivery method for gene therapy into the CNS leading to an increasing number of clinical trials, including recent successes for the retinal degenerative disorder Leber’s congenital amaurosis typ…”
BackgroundMarcó, S., Haurigot, V., & Bosch, F. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.217 · Cited by 41
“61,62 63–67 This overview will focus on in vivo gene therapies for MPSIII.”
Emmanuel, S. N., Mietzsch, M., Tseng, Y.-S., Smith, J. K., & Agbandje‐McKenna, M. (2021) · Viral Immunology · doi:10.1089/vim.2020.0022 · Cited by 33
“Despite the success of AAV vectors in gene delivery, obstacles remain for full realization of the system (86).”
BackgroundNakamura, A., Ali, S. A., & Kapoor, M. (2020) · Bone · doi:10.1016/j.bone.2020.115461 · Cited by 36
“transduce different cell types and tissues, and its low risk of immunogenicity [63].”
BackgroundZeng, C., Møller-Tank, S., Asokan, A., & Dragnea, B. G. (2017) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.6b10131 · Cited by 37
Lu, M., Zhao, X., Xing, H., Xun, Z., Yang, T., Cai, C., Wang, D., & Ding, P. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.03.043 · Cited by 33
Bočkor, L., Bortolussi, G., Iaconcig, A., Chiaruttini, G., Tiribelli, C., Giacca, M., Benvenuti, F., Zentilin, L., & Muro, A. F. (2017) · Gene Therapy · doi:10.1038/gt.2017.75 · Cited by 32
Sustained inhibition of hepatitis B virus replication in vivo using RNAi-activating lentiviruses
Ivacik, D., Ely, A., Ferry, N., & Arbuthnot, P. B. (2014) · Gene Therapy · doi:10.1038/gt.2014.94 · Cited by 34
Prophylaxis for hemophilia A without inhibitors: treatment options and considerations
Valentino, L. A., & Khair, K. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1775576 · Cited by 33
Khan, A., Aljarbou, A. N., Aldebasi, Y. H., Allemeilam, K. S., Alsahly, M. A., Khan, S., Alruwetei, A. M., & Khan, M. A. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s256022 · Cited by 32
Yin, S., Ma, L., Shao, T., Zhang, M., Guan, Y., Wang, L., Hu, Y., Chen, X., Han, H., Shen, N., et al. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1744-6 · Cited by 39
Ferla, R., Claudiani, P., Savarese, M., Kozarsky, K., Parini, R., Scarpa, M., Donati, M. A., Sorge, G., Hopwood, J. J., Parenti, G., et al. (2015) · Human Gene Therapy · doi:10.1089/hum.2014.109 · Cited by 35
Hironaka, K., Yamazaki, Y., Hirai, Y., Yamamoto, M., Miyake, N., Miyake, K., Okada, T., Morita, A., & Shimada, T. (2015) · Scientific Reports · doi:10.1038/srep13104 · Cited by 33
The CRISPR/Cas9 system for gene editing and its potential application in pain research
Sun, L., Marie, L. B., & Yuan-Xiang, T. (2016) · Translational Perioperative and Pain Medicine · doi:10.31480/2330-4871/040 · Cited by 43
“Although adenoviral, adeno-associated viral (AAV), and lentiviral vectors have been applied for delivery of the CRISPR/Cas9 system in vivo [12,66,67], AAV vectors are the most promising in vivo vehicles because they have little immunogenic potential or endogenous vector recombination [68] and a broad range of serotype…”
BackgroundAAV6 Vexosomes Mediate Robust Suicide Gene Delivery in a Murine Model of Hepatocellular Carcinoma
Khan, N., Maurya, S., Bammidi, S., & Jayandharan, G. R. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.006 · Cited by 33
Hakim, C. H., Yue, Y., Shin, J., Williams, R. R., Zhang, K., Smith, B. F., & Duan, D. (2014) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2014.2 · Cited by 33
Jiang, H., Huang, S., Li, X., Li, X., Zhang, Y., & Chen, Z.-Y. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.304405 · Cited by 31
Da Costa, R., Röger, C., Segelken, J., Barben, M., Grimm, C., & Neidhardt, J. (2016) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.16-19701 · Cited by 32
“differentiated retinal cells and to ameliorate genetic conditions.(5,6) Among the AAV capsid serotypes that have been tested”
BackgroundKrotova, K. Y., Day, A., & Aslanidi, G. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.10.001 · Cited by 32
Gene therapy for inherited metabolic diseases
Yılmaz, B. Ş., Gurung, S., Perocheau, D. P. B., Counsell, J. R., & Baruteau, J. (2020) · PubMed Central · doi:10.34763/jmotherandchild.20202402si.2004.000009 · Cited by 39
PAM-flexible Cas9-mediated base editing of a hemophilia B mutation in induced pluripotent stem cells
Hiramoto, T., Kashiwakura, Y., Hayakawa, M., Baatartsogt, N., Kamoshita, N., Abe, T., Inaba, H., Nishimasu, H., Uosaki, H., Hanazono, Y., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00286-w · Cited by 31
“2 Although AAV vectors enable long-term transgene expression in quiescent cells, cell division dilutes the AAV genome, resulting in the loss of therapeutic effect 3 .”
Maepa, M. B., Ely, A., Grayson, W., & Arbuthnot, P. B. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.04.007 · Cited by 32
“AAVs are well characterized, have a good safety profile, and use of the vectors has extensively been evaluated in clinical trials.(39) The utility of AAVs was exploited here to generate hepatotropic self-complementary particles that delivered silencing sequences to the liver.”
BackgroundEngineering T7 bacteriophage as a potential DNA vaccine targeting delivery vector
Xu, H., Bao, X., Wang, Y., Xu, Y. M., Deng, B., Lu, Y., & Hou, J. (2018) · Virology Journal · doi:10.1186/s12985-018-0955-1 · Cited by 32
Breaking genetic shackles: The advance of base editing in genetic disorder treatment
Xu, F., Zheng, C., Xu, W., Zhang, S., Liu, S., Chen, X., & Yao, K. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1364135 · Cited by 35
“…repair genetic defects in patients through approaches like gene replacement, gene addition, or stem cell transplantation, but these methods encountered various issues, including technical complexity, precision control challenges, and high costs (Mingozzi and High, 2011; Ragni, 2021; Weber, 2021).”
Background
Metadata
- Authors
- Mingozzi, F., & High, K. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Corresponding author
- High, Katherine A.
- Venue
- Nature Reviews Genetics
- Published
- 2011-04-18
- Volume
- 12
- Issue
- 5
- Pages
- 341-355
- ISSN
- 1471-0056 (ISSN-L)
- 1471-0064
- OpenAlex
- W2012894204
- Cited by
- 893
- References
- 177
- Citations by year
- 2026: 13 · 2025: 30 · 2024: 51 · 2023: 39 · 2022: 43 · 2021: 53 · 2020: 66 · 2019: 62 · 2018: 66 · 2017: 80 · 2016: 70 · 2015: 82 · 2014: 74 · 2013: 73 · 2012: 65
- FWCI
- 7.96
- Type
- journal article
- Language
- en
- Update notices
- erratum (2011-05-24)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- National Heart, Lung, and Blood Institute (P01HL064190, HL64190, HL078810, P01HL078810)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Keywords
- adeno-associated virus vectors, gene therapy, in vivo gene delivery, genetic disorders, gene replacement, inherited retinal disease, hemophilia B
- MeSH terms
- Dependovirus, Animals, Hemophilia B, Clinical Trials as Topic, Dogs, Genetic Vectors, Humans, Male, Retinal Diseases, Genetic Therapy, Gene Transfer Techniques, Genetic Diseases, Inborn, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.